Steven Brugger is the founder of Affinivax. Affinivax has raised $226M in total funding. Latest round: Series B. Based in Cambridge, United States.
Steven Brugger is the CEO of Affinivax, a clinical stage biotechnology company that uses its novel Multiple Antigen Presentation System (MAPS) technology platform for vaccines and immunotherapies. The company has secured funding from investors including the Bill & Melinda Gates Foundation, Viking Global Investors, Bain Capital Life Sciences, and Ziff Capital Partners. Affinivax is advancing its MAPS pneumococcal vaccine program and additional vaccine candidates targeting hospital-associated infections into clinical studies.
Full founder directory · Investor directory · Company funding database · Fundraising library